Alteogen Signed an Exclusive License Agreement with Sandoz to Develop and Commercialize Biosimilar Products
Shots:
- Alteogen will receive an up front & additional fees upon achievement of development, regulatory & sales milestones along with royalties on sales of the commercialized product
- Sandoz to get the global rights to use Alteogen’s ALT-B4, a novel hyaluronidase derived developed using Hybrozyme technology to develop & commercialize the SC version of a Sandoz biosimilar product & also obtain an option to license the Hybrozyme technology for 2 products
- Alteogen will be responsible for the regulatory, development & commercial supply of ALT-B4 to Sandoz. At the time of each option's exercise, both companies will negotiate separate agreements for 2 option products & responsible for an additional products that Sandoz may decide to develop
Ref: Businesswire | Image: Alteogen
Related News: Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar- aflibercept) in Korea
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
